Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

5.15
-0.2400-4.45%
Post-market: 5.160.0113+0.22%19:47 EDT
Volume:5.58M
Turnover:28.87M
Market Cap:927.45M
PE:-12.21
High:5.44
Open:5.40
Low:5.14
Close:5.39
52wk High:6.88
52wk Low:1.33
Shares:180.09M
Float Shares:119.00M
Volume Ratio:3.25
T/O Rate:4.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4216
EPS(LYR):-0.4216
ROE:-41.29%
ROA:-25.29%
PB:4.71
PE(LYR):-12.21

Loading ...

Company Profile

Company Name:
Compass Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
39
Office Location:
80 Guest Street,Suite 601,Boston,Massachusetts,United States
Zip Code:
02135
Fax:
- -
Introduction:
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.